Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 317-329

  Huizing, M T ^a   Giaccone, G ^a   van Warmerdam, L J ^a   Rosing, H ^a   Bakker, P J ^a   Vermorken, J B ^a   Postmus, P E ^a   van Zandwijk, N ^a   Koolen, M G ^a   ten Bokkel Huinink, W W ^a   van der Vijgh, W J ^a   Bierhorst, F J ^a   Lai, A ^a   Dalesio, O ^a   Pinedo, H M ^a   Veenhof, C H ^a   Beijnen, J H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; CLEMASTINE; DEXAMETHASONE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PACLITAXEL;

AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 8044220286     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.317     Document Type: Article

References (41)

1. Ginsberg RJ, Kris MG, Armstrong JG: Cancer of the lung, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, vol 1 (ed 4). Philadelphia, PA, Lippincott, 1993, pp 673-723
2. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
3. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-387, 1993
4. Chang AY, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
5. Pawel JV, Wagner H, Gatzemeier U, et al: Phase II study with paclitaxel (Taxol) in advanced inoperable NSCLC. Ann Oncol 5:155, 1994 (suppl 5, abstr)
6. Tester W, Cohn J, Desai A, et al: Phase II study of short infusion paclitaxel in patients with stage IV non - small-cell lung cancer. Proc Am Soc Clin Oncol 14:382, 1995 (abstr)
7. Bonomi PD, Finckelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non - small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
8. Parker RJ, Dabholkar MD, Lee KB, et al: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst 15:83-88, 1993
9. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727-733, 1993
10. Liebmann JE, Fisher J, Teague D, et al: Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6:25-31, 1994
11. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequence of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
12. Holmes FA, Newman RA, Madden T, et al: Schedule dependent pharmacokinetics in a phase I trial of Taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. Ann Oncol 5:197, 1994 (suppl 5, abstr)
13. Kennedy MJ, O'Reilly S, Donehower RC, et al: A phase I and pharmacologic study of sequence-dependent effects of paclitaxel and cyclophosphamide in doxorubicin-resistant metastatic breast cancer. Ann Oncol 5:198, 1994 (suppl 5, abstr)
14. Giaccone G, Huizing MT, Postmus P, et al: Dose-finding study of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 22:78-82, 1995 (suppl 9)
15. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
16. Willey TA, Bekos EJ, Gaver RC, et al: A high performance liquid chromatographic procedure for the quantitative determination of paclitaxel in human plasma. J Chromatogr 621:231-236, 1993
17. Huizing MT, Sparreboom A, Rosing H, et al: Quantification of paclitaxel metabolites in human plasma. J Chromatogr 674:261-268, 1995
18. Sparreboom A, Huizing MT, Boessen JJB, et al: Isolation, purification and biological activity of mono-dihydroxylated paclitaxel (Taxol) metabolites from human faeces. Cancer Chemother Pharmacol 36:227-232, 1995
19. Van Warmerdam LJC, Van Tellingen O, Maes RAA, et al: Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351:1820-1824, 1995
20. Proost JH, Meijer DKF: MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22:155-163, 1992
21. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982, pp 409-417
22. Van Warmerdam LJC, Huizing MT, Giaccone G, et al: Clinical pharmacology of carboplatin administered in alternating sequence with paclitaxel in patients with non-small cell lung cancer: A European Cancer Centre (ECC) study, in Pinedo HM, Schornagel JH (eds): Platinum and other methal coordination compounds in cancer chemotherapy 2 (ed 1 ), New York, NY, Plenum Press, 1996, pp 67-82
23. McGuire WP, Hoskins WJ, Brady MF, et al: Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc Am Soc Clin Oncol 14:275, 1995 (abstr)
24. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
25. LeBlanc GA, Sundseth SS, Weber GF, et al: Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 54:540-547, 1992
26. Micetich KC, Barnes D, Erickson LC: A comparative study of the cytotoxicity and DNA-damaging effects of cis(diammino)(1,1-cyclobutanedicarboxylato)-platinum (II) and cis-diamminedichloro-platinum (II) in L1210 cells. Cancer Res 45:4043-4047, 1985
27. Huizing MT, Vermorken JB, Rosing H, et al: Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3 hour paclitaxel infusion: A European Cancer Centre (ECC) trial. Ann Oncol 6:699-704, 1995
28. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationship in humans. J Clin Oncol 13:180-190, 1995
29. Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
30. Walle T, Walle K, Kumar G, et al: Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506-512, 1995
31. Reyno LM, Egorin MJ, Canetta RM, et al: Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11:1156-1164, 1993
32. Kearns CM, Belani CP, Erkmen K, et al: Reduced platelet toxicity with combination carboplatin and paclitaxel. Pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Soc Clin Oncol 14:170, 1995 (abstr)
33. Paul D, DeVore RD, Hande K, et al: Phase II trial of carboplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:361, 1995 (abstr)
34. Ten Bokkel Huinink WW, Veenhof CHN, Helmerhorst THJM, et al: Carboplatin and paclitaxel in patients with advanced ovarian cancer: A dose-finding study. Proc Am Soc Clin Oncol 14:361, 1995 (abstr)
35. Pluznik DH, Lee NS, Sawada T: Taxol induces the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA. Cancer Res 54:4150-4154, 1994
36. Bertoncello I, Kriegler AB, Woodcock DM, et al: Haematopoietic radioprotection by Cremophor EL: A polyethoxylated castor oil. Int J Radiat Biol 67:57-64, 1995
37. Jianguo M, Verweij J, Planting ASTH, et al: Docetaxel (Taxotere) and paclitaxel (Taxol) inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leucocytes (WBC). Br J Cancer (in press)
38. Langer CJ, Leighton J, Comis R, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non - small-cell lung cancer: A phase II toxicity, response and survival analysis. J Clin Oncol 13:1860-1870, 1995
39. Vafai D, Israel V, Zaretsky S, et al: Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:1067, 1995 (abstr)
40. Liebmann JE, Cook JA, Lipshultz C, et al: Cytotoxic studies of paclitaxel in human tumour cell lines. Br J Cancer 68:1104-1109, 1993
41. Georgiadis MS, Russell E, Johnson BE: Prolonging the exposition of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Proc Int Assoc Study Lung Cancer 11:95, 1994 (abstr)